EGFR and metastatic neoplasm: TKIs prolong survival significantly in patients with metastatic disease and EGFR-mutated tumors.43 Tyrosine kinase inhibitors were used in our cohort for recurrent disease, thus, explaining the discrepancy between shorter DFS yet similar OS between the driver mutation and the no-driver mutation groups (Figure 2).